Page last updated: 2024-08-21

isoxazoles and zirconium

isoxazoles has been researched along with zirconium in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dongen, GA; Hooge, MN; Jensen, MR; Jong, JR; Korte, MA; Nagengast, WB; Oude Munnink, TH; Quadt, C; Schröder, CP; Timmer-Bosscha, H; Vries, EG1
de Jong, JR; de Korte, MA; de Vries, EG; den Dunnen, WF; Garcia-Echeverria, C; Hollema, H; Jensen, MR; Lub-de Hooge, MN; Nagengast, WB; Oude Munnink, TH; Quadt, C; Schröder, CP; Timmer-Bosscha, H; van Dongen, GA1
Akimov, M; Banerji, U; Bongaerts, AH; Brouwers, AH; Chua, S; de Vries, EG; Fernandez-Ibarra, C; Gaykema, SB; Lub-de Hooge, MN; Oude Munnink, TH; Schröder, CP; Swanton, C; Vitfell-Rasmussen, J1
de Vries, EGE; Giesen, D; Kol, A; Lub-de Hooge, MN; Pool, M; Terwisscha van Scheltinga, AGT1

Other Studies

4 other study(ies) available for isoxazoles and zirconium

ArticleYear
(89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Mice; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radioisotopes; Receptor, ErbB-2; Resorcinols; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zirconium

2010
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Immunohistochemistry; Isoxazoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Resorcinols; Tissue Distribution; Vascular Endothelial Growth Factor A; Zirconium

2010
89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15

    Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radioisotopes; Resorcinols; Zirconium

2014
    European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Feasibility Studies; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Mice; Positron-Emission Tomography; Proto-Oncogene Proteins c-met; Radioisotopes; Resorcinols; Up-Regulation; Zirconium

2017